3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Pemetrexed
22
Carboplatin
22
Cisplatin
19
Paclitaxel
9
Gemcitabine
9
pembrolizumab
8
osimertinib
7
Nivolumab
6
Crizotinib
6
durvalumab
5
atezolizumab
5
amivantamab
4
Ipilimumab
4
Docetaxel
4
Afatinib
4
tremelimumab
3
lazertinib
3
Vinorelbine
3
Gefitinib
3
Etoposide
3
Albumin-Bound Paclitaxel
3
trametinib
2
selpercatinib
2
lorlatinib
2
larotrectinib
2
dabrafenib
2
cemiplimab
2
binimetinib
2
alectinib
2
PM 01183
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has announcements
×
dostarlimab
×
Thoracic
×
Clear all
NCT02715284
2026-01-13
GARNET
Tesaro, Inc.
Phase 1
Active not recruiting
730 enrolled
3 FDA